Cardiovasc
This article was originally published in Start Up
Executive Summary
Cardiovasc has a technology for growing functional endothelial cells in places where they normally do not grow. The company's two-part platform is built on a surface activation process that covalently bonds agents to materials, and a synthetic peptide, P-15, that attracts and anchors endothelial cells. The company's initial product will be a catheter-delivered stent, coated with the peptide, designed to encourage complete endothelialization and renew the interiors of aged and failing saphenous vein coronary bypass grafts.
You may also be interested in...
Cardiovascular devices
Two areas of heart disease in want of therapeutic solutions are attracting device innovation: atrial fibrillation and congestive heart failure. Successful developers will be rewarded by large markets with little in terms of current competition.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.